5KW.F SKINBIO THERAP LS-01

Healthcare Biotechnology Frankfurt Exchange
0.0380 EUR
Close of Nov 11, 2026
0.0380 0.2300
Market cap
EUR 9.85M
P/E
-
P/B
1.03x
ROE
-7.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2025.

Is 5KW.F undervalued?

Graham number

The Graham number of SKINBIO THERAP LS-01 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

SKINBIO THERAP LS-01 fundamental analysis

No fundamental analysis for SKINBIO THERAP LS-01 yet.

SKINBIO THERAP LS-01 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About SKINBIO THERAP LS-01

SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix whic…

Full company profile